MD Anderson Study Uses ImpediMed L-Dex Bioimpedance Spectroscopy to Assess Correlation with Limb Volume, Lymphatic Function in Lymphedema, Recommends L-Dex
BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov 15, 2018--Publication of a new study to assess the validity of L-Dex bioimpedance spectroscopy (BIS) measurements for evaluating the effectiveness of interventions to treat lymphedema concludes that the L-Dex correlates most closely with all measures and is the recommended metric when using BIS. Using technology from ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using BIS, the research team compared three L-Dex BIS metrics. Findings support the adjunctive use of the L-Dex ratio with limb volume measurements for objective diagnosis, evaluation of lymphedema severity, longitudinal serial evaluation of lymphedema, and response to conservative and surgical interventions.
BIS is an established tool for the measurement of extracellular fluid in lymphedema, which most commonly occurs secondary to cancer treatment, with the upper extremity most frequently affected following breast cancer therapy. In the study entitled, Correlation of L-Dex Bioimpedance Spectroscopy with Limb Volume and Lymphatic Function in Lymphedema, researchers assert that the diagnosis, staging, and longitudinal surveillance of lymphedema remains challenging due to the often poor correlation between clinical examination findings and physiological lymphatic function, and issues of reliability and validity of the measurement tools currently available.
The purpose of this study was to analyze the face, construct and criterion validity of BIS measurements using L-Dex in patients undergoing non-operative and operative therapy for both early established, and chronic, upper and lower extremity lymphedema. Researchers conducted a retrospective study of consecutive patients with lymphedema referred to a specialist lymphedema surgical service in a six-month period from April to September 2017.
Richard Carreon, managing director and CEO, ImpediMed says, “A recommendation from this prestigious research team at MD Anderson regarding the use of the BIS L-Dex ratio provides further credibility and is expected to impact utilization of this non-invasive technology. Early detection and continued monitoring of lymphedema can alter the severity and natural history of this devastating disorder, bringing improved healthcare outcomes and quality of life for millions of cancer survivors.”
Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO ® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181115005642/en/
KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS HOSPITALS MEDICAL DEVICES ONCOLOGY RESEARCH SCIENCE MANAGED CARE
Copyright Business Wire 2018.
PUB: 11/15/2018 10:36 AM/DISC: 11/15/2018 10:35 AM